{
    "root": "2fb43adf-3e71-176f-e063-6394a90a29e0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cefdinir",
    "value": "20250306",
    "ingredients": [
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "GUAR GUM",
            "code": "E89I1637KE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13446"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "STRAWBERRY",
            "code": "4J2TY8Y81V",
            "drugbank_id": "https://go.drugbank.com/drugs/DB10571"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "CEFDINIR",
            "code": "CI0FAO63WC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3485"
        }
    ],
    "indications": {
        "text": "reduce development drug-resistant bacteria maintain effectiveness cefdinir oral suspension antibacterial drugs , cefdinir oral suspension used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy . cefdinir oral suspension indicated treatment patients mild moderate infections caused susceptible strains designated microorganisms conditions listed .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "( usage indicated pathogens ) recommended duration treatment infections pediatric patients described following chart ; total daily dose infections 14 mg/kg , maximum dose 600 mg per day . once-daily dosing 10 days effective bid dosing . once-daily dosing studied skin infections ; therefore , cefdinir oral suspension administered twice daily infection . cefdinir oral suspension may administered without regard meals . pediatric patients ( age 6 months 12 years ) header $ type infection duration acute bacterial otitis media 7 mg/kg q12h 5 10 days 14 mg/kg q24h 10 days acute maxillary sinusitis 7 mg/kg q12h 10 days 14 mg/kg q24h 10 days pharyngitis/tonsillitis 7 mg/kg q12h 5 10 days 14 mg/kg q24h 10 days uncomplicated skin skin structure infections 7 mg/kg q12h 10 days cefdinir oral suspension pediatric chart apediatric patients weight \u226543 kg receive maximum daily dose 600 mg. header $ weight 125 mg/5 ml 250 mg/5 ml 9 kg/20 lbs 2.5 ml q12h 5 ml q24h 125 mg/5 ml product 18 kg/40 lbs 5 ml q12h 10 ml q24h 2.5 ml q12h 5 ml q24h 27 kg/60 lbs 7.5 ml q12h 15 ml q24h 3.75 ml q12h 7.5 ml q24h 36 kg/80 lbs 10 ml q12h 20 ml q24h 5 ml q12h 10 ml q24h \u226543 kg a/95 lbs 12 ml q12h 24 ml q24h 6 ml q12h 12 ml q24h",
        "doid_entities": [
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "acute maxillary sinusitis (DOID:2050)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2050"
            },
            {
                "text": "maxillary sinusitis (DOID:2051)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2051"
            },
            {
                "text": "sinusitis (DOID:0050127)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050127"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute bacterial otitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "warningsAndPrecautions": "cefdinir oral suspension usp , off-white creamish powder formulation , reconstituted directed , contains 125 mg cefdinir/5 ml 250 mg cefdinir/5 ml . reconstituted suspension off-white creamish color strawberry flavor . powder available follows : 125 mg/5 ml : 100 ml bottles ndc 68071-3806-1 store dry powder reconstituted suspension 20\u00b0 25\u00b0 c ( 68\u00b0 77\u00b0 f ) ; [ usp controlled room temperature ] .",
    "adverseReactions": "cefdinir contraindicated patients known allergy cephalosporin class antibiotics .",
    "indications_original": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension and other antibacterial drugs, cefdinir for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.\n                  Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.",
    "contraindications_original": "(see\n \n  \n                        INDICATIONS AND USAGE\n                     for Indicated Pathogens)\n\n \n                  The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, cefdinir for oral suspension should be administered twice daily in this infection. Cefdinir for oral suspension may be administered without regard to meals.\n                  \n                     Pediatric Patients (Age 6 Months Through 12 Years)\n                     \n                     \n                     \n                     \n                        \n                           \n                              Header$Type\u00a0of\u00a0Infection\n                              \n                           \n                           \n                              Dosage\n                              \n                           \n                           \n                              Duration\n                              \n                           \n                        \n                        \n                           Acute\u00a0Bacterial\u00a0Otitis\u00a0Media \n     \n                           \n                           7\u00a0mg/kg\u00a0q12h\u00a0or \n     \n                           \n                           5\u00a0to\u00a010\u00a0days \n     \n                           \n                        \n                        \n                           \n                           14\u00a0mg/kg\u00a0q24h \n     \n                           \n                           10\u00a0days \n     \n                           \n                        \n                        \n                           Acute\u00a0Maxillary\u00a0Sinusitis \n     \n                           \n                           7\u00a0mg/kg\u00a0q12h\u00a0or \n     \n                           \n                           10\u00a0days \n     \n                           \n                        \n                        \n                           \n                           14\u00a0mg/kg\u00a0q24h \n     \n                           \n                           10\u00a0days \n     \n                           \n                        \n                        \n                           Pharyngitis/Tonsillitis \n     \n                           \n                           7\u00a0mg/kg\u00a0q12h\u00a0or \n     \n                           \n                           5\u00a0to\u00a010\u00a0days \n     \n                           \n                        \n                        \n                           \n                           14\u00a0mg/kg\u00a0q24h \n     \n                           \n                           10\u00a0days \n     \n                           \n                        \n                        \n                           Uncomplicated\u00a0Skin\u00a0and Skin\u00a0Structure\u00a0Infections \n     \n                           \n                           7\u00a0mg/kg\u00a0q12h \n     \n                           \n                           10\u00a0days \n     \n                           \n                        \n                     \n                  \n                  \n                     CEFDINIR FOR ORAL SUSPENSION PEDIATRIC DOSAGE CHART\n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 aPediatric patients who weight \u226543 kg should receive the maximum daily dose of 600 mg.\n    \n     \n                           \n                        \n                     \n                     \n                        \n                           \n                              Header$Weight\u00a0\n                              \n                           \n                           \n                              125\u00a0mg/5\u00a0mL\n                              \n                           \n                           \n                              250\u00a0mg/5\u00a0mL\n                              \n                           \n                        \n                        \n                           9\u00a0kg/20\u00a0lbs \n     \n                           \n                           2.5\u00a0mL\u00a0q12h\u00a0or\u00a05\u00a0mL\u00a0q24h \n     \n                           \n                           Use\u00a0125\u00a0mg/5\u00a0mL\u00a0product \n     \n                           \n                        \n                        \n                           18\u00a0kg/40\u00a0lbs \n     \n                           \n                           5\u00a0mL\u00a0q12h\u00a0or\u00a010\u00a0mL\u00a0q24h \n     \n                           \n                           2.5\u00a0mL\u00a0q12h\u00a0or\u00a05\u00a0mL\u00a0q24h \n     \n                           \n                        \n                        \n                           27\u00a0kg/60\u00a0lbs \n     \n                           \n                           7.5\u00a0mL\u00a0q12h\u00a0or\u00a015\u00a0mL\u00a0q24h \n     \n                           \n                           3.75\u00a0mL\u00a0q12h\u00a0or\u00a07.5\u00a0mL\u00a0q24h \n     \n                           \n                        \n                        \n                           36\u00a0kg/80\u00a0lbs \n     \n                           \n                           10\u00a0mL\u00a0q12h\u00a0or\u00a020\u00a0mL\u00a0q24h \n     \n                           \n                           5\u00a0mL\u00a0q12h\u00a0or\u00a010\u00a0mL\u00a0q24h \n     \n                           \n                        \n                        \n                           \u226543\u00a0kg\n    \n     a/95\u00a0lbs \n     \n                           \n                           12\u00a0mL\u00a0q12h\u00a0or\u00a024\u00a0mL\u00a0q24h \n     \n                           \n                           6\u00a0mL\u00a0q12h\u00a0or\u00a012\u00a0mL\u00a0q24h",
    "warningsAndPrecautions_original": "Cefdinir for oral suspension USP, is an off-white to creamish powder formulation that, when reconstituted as directed, contains 125 mg cefdinir/5 mL or 250 mg cefdinir/5 mL. The reconstituted suspension has an off-white to creamish color and strawberry flavor. The powder is available as follows:\n                  125 mg/5 mL:\n                  100 mL bottles                                     NDC 68071-3806-1\n                  \n                  \n                     Store dry powder and reconstituted suspension at 20\u00b0 to 25\u00b0 \n  C (68\u00b0 to 77\u00b0 \n  F); [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.",
    "drug": [
        {
            "name": "Cefdinir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3485"
        }
    ]
}